

# Julius Popp

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2426964/julius-popp-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

3,997  
citations

32  
h-index

60  
g-index

155  
ext. papers

5,583  
ext. citations

5.6  
avg. IF

5.13  
L-index

#	Paper	IF	Citations
119	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
118	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 27	19	1
117	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 840651	5.3	0
116	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , <b>2022</b> ,	36.3	27
115	Effects of age, amyloid, sex, and $\beta$ on the CSF proteome in normal cognition.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2022</b> , 14, e12286	5.2	
114	Factors associated with subjective cognitive decline in dementia-free older adults-A population-based study. <i>International Journal of Geriatric Psychiatry</i> , <b>2021</b> , 36, 1188-1196	3.9	8
113	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1452-1464	1.2	4
112	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 65	9	13
111	An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 71	9	11
110	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1628-1640	1.2	4
109	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , <b>2021</b> , 12, 3417	17.4	23
108	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 712545	5.3	3
107	The power of personality in successful ageing: a comprehensive review of larger quantitative studies. <i>European Journal of Ageing</i> , <b>2021</b> , 18, 269-285	3.6	4
106	Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2021</b> , 205, 105785	5.1	4
105	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , <b>2021</b> , 9,	4.6	2
104	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e036954	1.2	1
103	An integrative, hypothesis-free, multi-omics approach uncovers biological pathway alterations in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e038563	1.2	

102	Determinants of subjective cognitive decline in dementia-free older adults: A population-based study. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e038805	1.2	
101	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042739	1.2	
100	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045853	1.2	
99	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e046102	1.2	
98	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047247	1.2	1
97	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 213-225	4.3	10
96	Early-Stage Alzheimer's Disease Does Not Alter Pupil Responses to Colored Light Stimuli. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 75, 1273-1282	4.3	5
95	APOE ε genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 65	9	13
94	Salivary cortisol and five-year change in cognitive performance in non-demented elderly subjects: a population-based study. <i>Neurobiology of Aging</i> , <b>2020</b> , 94, 34-37	5.6	1
93	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 1025-1044	14.3	18
92	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease <b>2020</b> , ,		1
91	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , <b>2020</b> , 143, 3776-3792	11.2	16
90	Preoperative Cognitive Impairment and Postoperative Delirium Predict Decline in Activities of Daily Living after Cardiac Surgery-A Prospective, Observational Cohort Study. <i>Geriatrics (Switzerland)</i> , <b>2020</b> , 5,	2.2	3
89	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 403	8.6	10
88	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1353-1368	4.3	4
87	Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. <i>Molecular Medicine</i> , <b>2020</b> , 26, 34	6.2	10
86	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1478-1488	1.2	22
85	Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults. <i>Journal of Proteome Research</i> , <b>2019</b> , 18, 1162-1174	5.6	15

84	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 817-827	1.2	26
83	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 776-787	1.2	74
82	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 644-654	1.2	57
81	Preoperative Depression and Plasma Cortisol Levels as Predictors of Delirium after Cardiac Surgery. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2019</b> , 48, 207-214	2.6	8
80	High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 43	5.3	104
79	P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE <b>2019</b> , 15, P1515-P1516		
78	ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS <b>2019</b> , 15, P1626-P1627		
77	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 933-938	6	29
76	Systemic and central nervous system metabolic alterations in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 93	9	57
75	A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects. <i>Analytica Chimica Acta</i> , <b>2018</b> , 1037, 327-337	6.6	34
74	Prevalence of the apolipoprotein E $\epsilon 4$ allele in amyloid $\beta$ -positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
73	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 64	9	31
72	Alzheimer disease pathology and the cerebrospinal fluid proteome. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 66	9	34
71	Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1640-1650	1.2	87
70	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
69	P3-418: INTEGRATIVE PREDICTION OF COGNITIVE DECLINE USING ATROPHY NETWORKS, CSF BIOMARKERS, AND GENOTYPE DATA <b>2018</b> , 14, P1267-P1267		
68	P2-270: INCREASED CSF AMYLOID- $\beta$ 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY <b>2018</b> , 14, P780-P781		
67	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT <b>2018</b> , 14, P1161-P1161		

66	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P204-P204		
65	P2-608: SALIVARY CORTISOL AND 5Y CHANGE IN COGNITIVE FUNCTION IN COMMUNITY DWELLING, COGNITIVELY HEALTHY OLDER ADULTS: THE PSYCOLAUS COHORT STUDY <b>2018</b> , 14, P972-P972		1
64	F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION <b>2018</b> , 14, P201-P202		
63	F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A $\beta$ APOE $\epsilon$ AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P201-P201		
62	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 100	9	30
61	P4-193: IDENTIFICATION AND COMPREHENSIVE CHARACTERIZATION OF CNS AND SYSTEMIC METABOLIC ALTERATIONS IN ALZHEIMER'S DISEASE <b>2018</b> , 14, P1513-P1514		
60	LC-HRMS data as a result of untargeted metabolomic profiling of human cerebrospinal fluid. <i>Data in Brief</i> , <b>2018</b> , 21, 1358-1362	1.2	2
59	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P895-P896		
58	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P202-P204		
57	The Effects of Hand Massage on Stress and Agitation Among People with Dementia in a Hospital Setting: A Pilot Study. <i>Applied Psychophysiology Biofeedback</i> , <b>2018</b> , 43, 319-332	3.4	4
56	Do diurnal cortisol levels mediate the association between sleep disturbances and cognitive impairment?. <i>Neurobiology of Aging</i> , <b>2018</b> , 69, 65-67	5.6	2
55	Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. <i>Brain, Behavior, and Immunity</i> , <b>2017</b> , 62, 203-211	16.6	63
54	Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 6	9	15
53	ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological Variability of the Human Ionome. <i>Journal of Proteome Research</i> , <b>2017</b> , 16, 2080-2090	5.6	32
52	One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 43	9	25
51	Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study. <i>Neurology</i> , <b>2017</b> , 88, 463-469	6.5	63
50	Life events, salivary cortisol, and cognitive performance in nondemented subjects: a population-based study. <i>Neurobiology of Aging</i> , <b>2017</b> , 51, 1-8	5.6	24
49	Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 273-281	4.3	22

48	Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. <i>Experimental Gerontology</i> , <b>2017</b> , 100, 45-53	4.5	17
47	Response to a letter to the editor: sleep disturbance as a stressor event in elderly's life. <i>Neurobiology of Aging</i> , <b>2017</b> , 60, 204	5.6	
46	Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 7, 107-114	5.2	19
45	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 1641-1652	4.3	13
44	Personality, Cortisol, and Cognition in Non-demented Elderly Subjects: Results from a Population-Based Study. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 63	5.3	21
43	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 159-170	4.3	19
42	P2-147: A Neuroinflammatory Biomarker Signature of Blood-Brain Barrier Impairment in Older Adults <b>2016</b> , 12, P670-P670		2
41	Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. <i>Journal of Neurochemistry</i> , <b>2016</b> , 139, 324-332	6	18
40	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
39	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1306-15	1.2	87
38	Behavioral and psychological symptoms and cognitive decline in patients with amnesic MCI and mild AD: a two-year follow-up study. <i>International Psychogeriatrics</i> , <b>2015</b> , 27, 1379-89	3.4	16
37	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 601-7	5.6	99
36	Delirium in the elderly: Current problems with increasing geriatric age. <i>Indian Journal of Medical Research</i> , <b>2015</b> , 142, 655-62	2.9	35
35	SUCLG2 identified as both a determinant of CSF A $\beta$ -42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6644-58	5.6	30
34	Subjective cognitive decline in patients with mild cognitive impairment and healthy older adults: association with personality traits. <i>Geriatrics and Gerontology International</i> , <b>2014</b> , 14, 589-95	2.9	25
33	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <i>Lancet Neurology</i> , <b>2013</b> , 12, 233-43 <sup>24.1</sup>		146
32	Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. <i>Biochemical Pharmacology</i> , <b>2013</b> , 86, 37-42	6	69
31	Delirium and cognitive decline: more than a coincidence. <i>Current Opinion in Neurology</i> , <b>2013</b> , 26, 634-9	7.1	11

30	Predisposing and precipitating factors of delirium after cardiac surgery: a prospective observational cohort study. <i>Annals of Surgery</i> , <b>2013</b> , 257, 1160-7	7.8	64
29	Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. <i>Journal of Neurochemistry</i> , <b>2012</b> , 123, 310-6	6	51
28	Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 31, 751-8	4.3	24
27	Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and Folate, in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2012</b> , 50, 1641-7	5.9	19
26	Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2012</b> , 7, 943-8	6.9	34
25	Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease. <i>Neuroscience Letters</i> , <b>2012</b> , 507, 10-5	3.3	16
24	Cerebrospinal fluid soluble amyloid- $\beta$ protein precursor as a potential novel biomarkers of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 119-25	4.3	38
23	Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. <i>Neurology</i> , <b>2012</b> , 79, 1332-9	6.5	207
22	Prevention and treatment options for postoperative delirium in the elderly. <i>Current Opinion in Psychiatry</i> , <b>2012</b> , 25, 515-21	4.9	18
21	Implications of objective vs subjective delirium assessment in surgical intensive care patients. <i>American Journal of Critical Care</i> , <b>2012</b> , 21, e12-20	1.7	38
20	Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , <b>2011</b> , 24, 556-61	4.9	18
19	Association of N-acetylaspartate and cerebrospinal fluid A $\beta$ 2 in dementia. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 27, 393-9	4.3	8
18	The role of macrophage migration inhibitory factor in Alzheimer's disease. <i>Molecular Medicine</i> , <b>2010</b> , 16, 116-21	6.2	61
17	Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOE $\epsilon$ 4 genotype. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 459-68	4.3	33
16	Volume loss of the medial temporal lobe structures in subjective memory impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2010</b> , 29, 75-81	2.6	118
15	S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Neurodegenerative Diseases</i> , <b>2010</b> , 7, 373-8	2.3	64
14	Alterations of cholesterol precursor levels in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2010</b> , 1801, 945-50	5	42
13	Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients. <i>Journal of Critical Care</i> , <b>2010</b> , 25, 144-51	4	132

12	Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 613-22	4.3	14
11	Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. <i>Journal of Psychiatric Research</i> , <b>2009</b> , 43, 749-53	5.2	57
10	RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. <i>Journal of Cellular and Molecular Medicine</i> , <b>2009</b> , 13, 589-98	5.6	24
9	Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. <i>Journal of the American Geriatrics Society</i> , <b>2009</b> , 57, 737-9	5.6	4
8	CSF cortisol in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 498-500	5.6	57
7	CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism. <i>European Psychiatry</i> , <b>2009</b> , 24, 183-90	6	29
6	Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 819-28	4.3	43
5	CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. <i>Brain Research</i> , <b>2008</b> , 1232, 1-6	3.7	21
4	Histologically confirmed amyloid deposition and low CSF Aβ42 in a cognitively normal subject. <i>Journal of Neurology</i> , <b>2007</b> , 254, 970-1	5.5	1
3	Mechanical ventilation in ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2004</b> , 13, 183-8	8.8	26
2	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
1	New insights on the genetic etiology of Alzheimer's and related dementia		25